Company Performance - Allogene Therapeutics (ALLO) has returned 25.6% year-to-date, significantly outperforming the average gain of 7.7% in the Medical sector [4] - The Zacks Consensus Estimate for ALLO's full-year earnings has increased by 3%, indicating improved analyst sentiment and earnings outlook [4] - Allogene Therapeutics holds a Zacks Rank of 2 (Buy), suggesting it is poised for potential outperformance in the near term [3] Industry Context - Allogene Therapeutics is part of the Medical - Biomedical and Genetics industry, which consists of 452 stocks and currently ranks 87 in the Zacks Industry Rank [6] - The average gain for stocks in the Medical - Biomedical and Genetics industry this year is 21.4%, indicating that ALLO is performing better than its industry peers [6] - Alzamend Neuro, Inc. (ALZN), another stock in the same industry, has also shown strong performance with a year-to-date return of 20.9% and a Zacks Rank of 2 (Buy) [5][6]

Company Overview - AIM ImmunoTech Inc. is a notable stock within the Medical sector, which consists of 932 individual stocks and ranks 6 in the Zacks Sector Rank [2] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook based on earnings estimates and revisions [3] Performance Analysis - AIM ImmunoTech Inc. has achieved a year-to-date return of approximately 14.2%, outperforming the average gain of 8.9% for Medical stocks [4] - The Zacks Consensus Estimate for AIM's full-year earnings has increased by 3.8% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4] Industry Context - AIM ImmunoTech Inc. is part of the Medical - Drugs industry, which includes 141 companies and currently ranks 81 in the Zacks Industry Rank. This industry has seen an average gain of 4.3% year-to-date, further highlighting AIM's superior performance [6] - In comparison, another stock in the Medical sector, Alzamend Neuro, Inc., has a year-to-date return of 28.6% and belongs to the Medical - Biomedical and Genetics industry, which ranks 107 and has gained 21.9% year-to-date [5][7]

Core Viewpoint - Alzamend Neuro, Inc. (ALZN) has experienced a decline of 8.9% in its stock price over the past two weeks, but the formation of a hammer chart pattern suggests a potential trend reversal due to increased buying interest [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, characterized by a small candle body and a long lower wick, suggesting that selling pressure may be exhausting [3][4]. - This pattern typically forms during a downtrend when bears dominate, but a subsequent buying interest can lead to a price increase, signaling a possible reversal [3][4]. Fundamental Analysis - Recent upward revisions in earnings estimates for ALZN serve as a bullish indicator, correlating strongly with near-term stock price movements [6]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 21.4%, indicating that analysts expect better earnings than previously predicted [7]. - ALZN holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [8].

Core Insights - Alzamend Neuro, Inc. is set to initiate a phase II clinical study of AL001 for Alzheimer's treatment in Q4 2025, following the successful completion of a key component by Tesla Dynamic Coils BV [1][2] - The study, in collaboration with Massachusetts General Hospital, aims to explore AL001's unique properties in lithium delivery to the brain, potentially offering targeted effectiveness and reduced side effects compared to existing lithium salts [2][3] Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [6] - The company's pipeline includes two novel therapeutic candidates: AL001, which utilizes patented ionic cocrystal technology for lithium delivery, and ALZN002, a cell-based therapeutic vaccine targeting beta-amyloid removal from the brain [6] Product Development - AL001 has shown promise in previous studies, demonstrating better brain absorption and lower blood lithium levels, which could lead to safer treatments [2][4] - The maximum tolerated dose (MTD) identified in a Phase IIA study is designed to minimize the need for therapeutic drug monitoring (TDM), potentially transforming the management of conditions like Alzheimer's [4][5] Market Potential - AL001 could eliminate the need for TDM, addressing the underutilization of lithium due to its complex monitoring requirements, thus improving treatment outcomes for vulnerable populations [3][5] - The advancement of AL001 is expected to enhance the lives of over 6.5 million Americans suffering from Alzheimer's, offering a more effective and user-friendly therapeutic option [5]

Core Viewpoint - Alzamend Neuro is set to initiate a phase II clinical study of AL001 for PTSD treatment in Q4 2025, following the successful completion of a key component for the trial [1][2]. Group 1: Clinical Development - The phase II study will be conducted in collaboration with Massachusetts General Hospital, focusing on AL001's unique properties and its effects on lithium delivery in the brain compared to existing lithium salts [2]. - Previous studies in mice indicated that AL001 allows for better brain absorption of lithium while maintaining lower blood levels, potentially leading to safer treatments [2][5]. Group 2: Treatment Implications - AL001 could eliminate the need for lithium therapeutic drug monitoring (TDM), which has historically complicated the use of lithium in treating bipolar disorder and PTSD [3]. - Current lithium salts have a narrow therapeutic window requiring regular monitoring, which limits their use; however, low doses of lithium carbonate have shown effectiveness in alleviating symptoms in PTSD patients [3][4]. Group 3: Market Potential - The introduction of AL001 could significantly enhance treatment options for over 9 million Americans suffering from PTSD, potentially reshaping treatment paradigms and improving patient quality of life [4]. - AL001 is designed to provide the benefits of marketed lithium salts while reducing associated toxicities, thus addressing the limitations of current lithium therapies [5]. Group 4: Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD [6]. - The company's pipeline includes AL001, a novel lithium-delivery system, and ALZN002, a cell-based therapeutic vaccine aimed at combating Alzheimer's disease [6].

As filed with the U.S. Securities and Exchange Commission on July 30, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ault Alliance, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 3679 (Primary Standard Industrial Classification Code Number) 94-1721931 (I.R.S. Employer Identification No.) 11411 Southern Highla ...